BioRegenx, Inc.
BRGX
$0.01
$0.0041.11%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -14.80% | -39.24% | -6.26% | -32.08% | -24.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.80% | -39.24% | -6.26% | -32.08% | -24.98% |
| Cost of Revenue | -28.85% | -64.61% | -34.04% | -54.07% | -48.77% |
| Gross Profit | -11.46% | -24.98% | 5.67% | -14.63% | -15.69% |
| SG&A Expenses | 76.14% | -69.55% | -82.72% | 216.28% | -91.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.09% | -68.81% | -80.50% | 188.30% | -71.70% |
| Operating Income | 97.40% | 89.68% | 93.75% | -894.42% | 86.74% |
| Income Before Tax | 79.59% | 83.88% | 91.53% | -7,068.13% | 84.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 79.59% | 83.88% | 91.53% | -7,068.13% | 84.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 79.59% | 83.88% | 91.53% | -7,068.13% | 84.32% |
| EBIT | 97.40% | 89.68% | 93.75% | -894.42% | 86.74% |
| EBITDA | -98.42% | 85.13% | 93.01% | -627.04% | 110.02% |
| EPS Basic | 75.00% | 83.33% | 92.68% | -4,625.00% | 90.24% |
| Normalized Basic EPS | 66.67% | 85.71% | 92.31% | -600.00% | 88.00% |
| EPS Diluted | 75.00% | 83.33% | 92.68% | -4,625.00% | 90.24% |
| Normalized Diluted EPS | 66.67% | 85.71% | 92.31% | -600.00% | 88.00% |
| Average Basic Shares Outstanding | 0.45% | 0.28% | 24.67% | 39.44% | 53.80% |
| Average Diluted Shares Outstanding | 0.45% | 0.28% | 24.67% | 39.44% | 53.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |